Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Packet of Tramadol tablets

Although tramadol is increasingly used to manage non-cancer pain, few safety studies have compared it with other opioids in actual practice conditions. A new study, published in JAMA, provides evidence that tramadol is associated with an increased risk of mortality and adverse clinical outcomes, and highlights the need for future research on its safety.

The population-based cohort study on 368,960 participants reviewed a new dispensation of tramadol, compared with codeine. The international research team prespecified eight outcomes that had been previously correlated to the opioid use including: all-cause mortality, cardiovascular events, fractures, constipation, delirium, falls, opioid abuse/dependence, and sleep disorders within one-year after the first dispensation. Codeine was used as the comparator as both tramadol and codeine are weak opioids, prescribed for addressing similar pain and illness.

Junqing Xie, DPhil student and lead author said: "Compared with codeine, our study showed that tramadol was associated with an increased risk of mortality, cardiovascular events, and fractures, but we saw no increased risk for the other measures we explored. The results for mortality are quite surprising because tramadol is accepted as being a safer opioid. The findings should be interpreted cautiously given the potential for residual confounding."

The findings were also consistent when applied over a range of subgroups, which means these effects could be seen in different age groups, and across different pain indications in adults.

The use of opioids to treat severe cancer and non-cancer pain has led to a decades-long epidemic in the United States where death rates and adverse effects on public health from opioid use are significant. Recently, more and more data show that the opioids have been increasingly prescribed for a variety of painful conditions in other countries like Canada, Australia, Europe and the UK. "The increased use of tramadol is a concern because if it's considered a safe drug, it might be prescribed more casually. We think while more data is urgently needed for the tramadol safety profile, clinicians should err on the side of caution when considering this treatment," concluded Carlen Reyes, a doctor and the corresponding author for this study.

Similar stories

Fiona Powrie honoured by British Society for Immunology

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

Vaccination safety: generating accurate evidence is the clearest path to creating public trust

A new study shows that a vaccine surveillance method in observational data may generate high number of false positives

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Single-cell ancestry vaccine research funded by the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.